MedWatch

Novo SVP on NASH collaboration with Gilead: "It's the first step"

Novo Nordisk and US-based Gilead Sciences have joined forces in a new clinical trial with the fatty liver disease NASH. Although the partnership only entails one study for now, it could kick off more collaborations in the field, says Novo's Head of Global Drug Discovery, who also anticipates similar agreements with other actors.

Foto: Novo Nordisk

Danish drug group Novo Nordisk already expressed interest in entering the lucrative market for treatment of non-alcoholic steatohepatitis (NASH).

This ambition was recently fueled by a new clinical collaboration between Novo and one of the world's leading actors in fatty liver diseases, US-based Gilead Sciences.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier